Major advances in genetic and epigenetic profiling of acute lymphoblastic leukaemia (ALL)
have enhanced the understanding of key biological subsets of de novo and relapsed ALL …

Advances in genomic research and risk-directed therapy have led to improvements in the
long-term survival and quality of life outcomes of patients with childhood acute lymphoblastic …

Acute lymphoblastic leukemia (ALL), the most common malignancy of childhood, is a
genetically complex entity that remains a major cause of childhood cancer‐related mortality …

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and a
leading case of childhood cancer death. The last decade has witnessed a transformation in …

Genomic profiling has transformed our understanding of the genetic basis of acute
lymphoblastic leukemia (ALL). Recent years have seen a shift from microarray analysis and …

Advancement in the diagnosis and treatment of pedi-atric acute lymphoblastic leukemia
(ALL) is one of the greatest successes of modern medicine. Over the past 50 years, there …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure
rates exceeding 90% in children, it remains an important cause of morbidity and mortality in …

Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer and an important
cause of morbidity from haematological malignancies in adults. In the past several years, we …

Despite impressive advances in cure rates for childhood acute lymphoblastic leukemia
(ALL), ALL remains the leading cause of disease-related death in young people and new …

Our understanding of the genetic basis of childhood acute lymphoblastic leukemia (ALL) has
been greatly advanced by genomic profiling and sequencing studies. These efforts have …